<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296725</url>
  </required_header>
  <id_info>
    <org_study_id>#4217R/#5294R</org_study_id>
    <secondary_id>continuation of IRB3112;</secondary_id>
    <secondary_id>became IRB5294R.</secondary_id>
    <nct_id>NCT00296725</nct_id>
  </id_info>
  <brief_title>Dichotic Listening as a Predictor of Medication Response in Depression</brief_title>
  <official_title>Dichotic Listening as a Predictor of Placebo and Medication Response in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depressed patients will have hearing tests and then be treated with up to three treatments
      (i.e., Fluoxetine, Imipramine and Placebo) until remitted, to see whether test results
      predict specific outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data suggest that depressed patients with increased left hemispheric laterality
      of perceptual processing are unlikely to improve during six weeks' treatment with placebo,
      while being very responsive to either imipramine or fluoxetine. Depressed patients who do not
      show evidence of poor right hemispheric functioning respond significantly more often to
      placebo than those with poor right hemispheric functioning, and do not show an advantage of
      drug over placebo. 100 depressed patients will be tested with verbal and nonverbal dichotic
      tests, and then treated sequentially with Placebo, Fluoxetine and Imipramine until remitted.
      Preferential hemisphere for auditory processing will be correlated with treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1994</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale (HAM-D)</measure>
    <time_frame>6 mos.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI)</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atypical Depression Diagnostic Scale (ADDS)</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deragotis Sexual Performance Scale</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaith-Hamilton Pleasure Scale</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spielberger State/Trait Anxiety Scale</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Major Depression</condition>
  <condition>Dysthymia</condition>
  <condition>Depressive Disorder NOS</condition>
  <arm_group>
    <arm_group_label>fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>imipramine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.</description>
    <arm_group_label>fluoxetine</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.</description>
    <arm_group_label>imipramine</arm_group_label>
    <other_name>Tofranil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages between 18-65

          -  Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS

        Exclusion Criteria:

          -  Known hearing impairment

          -  Active suicidal ideation (history of suicide attempts will be evaluated on a case by
             case basis)

          -  HAMD &gt; 20

          -  Current (past six months) alcohol and/or drug abuse or dependence

          -  Medical condition likely to require intervention contraindicated with study medication
             (e.g., known arrhythmia likely to be exacerbated by Imipramine)

          -  Bipolar I

          -  Psychosis

          -  If currently taking antidepressants or mood stabilizers, cannot be off psychotropic
             medication for 7 weeks (10 weeks for Prozac) or felt to require other psychiatric
             medication (other than occasional sleep or Anxiety medication)

          -  Premenopausal women not using known effective birth control

          -  Not currently depressed (whether considered due to current treatment or not)

          -  Nonresponse to adequate trial of both study medications (i.e., &gt; 4weeks on &gt;
             escitalopram 30 mg/d, and imipramine 200 mg/d); patients having an inadequate response
             to one study medication could be enrolled and receive the other; patients having
             responded to an adequate trial of either study medication would be offered a retrial;
             also excluded will be subjects having non responded to an adequate trial with
             citalopram (i.e., &gt; 4 weeks on &gt; citalopram 60 mg/d)

          -  Left-handed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan W. Stewart, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute - Columbia University Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Evaluation Service, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depression-nyc.org</url>
    <description>Depression Evaluation Service - official website</description>
  </link>
  <link>
    <url>http://www.nyspi.org</url>
    <description>New York State Psychiatric Institute - official website</description>
  </link>
  <reference>
    <citation>Bruder GE, Otto MW, McGrath PJ, Stewart JW, Fava M, Rosenbaum JF, Quitkin FM. Dichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic response. Neuropsychopharmacology. 1996 Aug;15(2):171-9.</citation>
    <PMID>8840353</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001 Mar 1;49(5):416-25.</citation>
    <PMID>11274653</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, McGrath PJ, Deliyannides D, Quitkin FM. Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men. Neuropsychopharmacology. 2004 Sep;29(9):1752-61.</citation>
    <PMID>15238992</PMID>
  </reference>
  <reference>
    <citation>Stewart JW, Quitkin FM, McGrath PJ, Bruder GE. Do tricyclic responders have different brain laterality? J Abnorm Psychol. 1999 Nov;108(4):707-10.</citation>
    <PMID>10609436</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, Voglmaier MM, Harrison WM, McGrath P, Tricamo E, Quitkin FM. Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology. 1990 Feb;3(1):1-10.</citation>
    <PMID>2306330</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Dysthymia</keyword>
  <keyword>Depression NOS</keyword>
  <keyword>Dichotic Listening</keyword>
  <keyword>Fluoxetine</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Placebo</keyword>
  <keyword>Predictors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 31, 2017</submitted>
    <returned>September 27, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

